Skip to main content
Livermore
Livermore
ZHEN

OrbiMed Advisors LLC's Form 4 filing

ADARx Pharmaceuticals, Inc. (ADRX) · filed Sep 30, 2026

Accession no.
0000947871-26-000910
Filed
Sep 30, 2026, 5:23 PM ET
Trade date
Sep 28, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 11 non-derivative transactions and 8 derivative transactions. Open-market purchases total $16.1M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 0001055951Director, 10% Owner
OrbiMed Israel GP II, L.P.CIK 0001682090Director, 10% Owner
OrbiMed Advisors Israel II LtdCIK 0001682093Director, 10% Owner
OrbiMed Capital GP VII LLCCIK 0001760648Director, 10% Owner
OrbiMed Genesis GP LLCCIK 0001808744Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 28, 2026Common StockCConversionAcquired+10,690,530–F1–10,690,530Indirect
Sep 28, 2026Common StockCConversionAcquired+2,000,962–F1–12,691,492Indirect
Sep 28, 2026Common StockCConversionAcquired+769,601–F1–13,461,093Indirect
Sep 28, 2026Common StockCConversionAcquired+564,187–F1–14,025,280Indirect
Sep 28, 2026Common StockPPurchaseAcquired+300,249$17.00+$5,104,23314,325,529Indirect
Sep 28, 2026Common StockCConversionAcquired+7,127,019–F1–7,127,019Indirect
Sep 28, 2026Common StockCConversionAcquired+1,333,975–F1–8,460,994Indirect
Sep 28, 2026Common StockCConversionAcquired+513,067–F1–8,974,061Indirect
Sep 28, 2026Common StockCConversionAcquired+256,448–F1–9,230,509Indirect
Sep 28, 2026Common StockPPurchaseAcquired+61,516$17.00+$1,045,7729,292,025Indirect
Sep 28, 2026Common StockPPurchaseAcquired+588,235$17.00+$9,999,995588,235Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 28, 2026Common StockCConversionDisposed−10,690,530$0.00$00Indirect
Sep 28, 2026Common StockCConversionDisposed−2,000,962$0.00$00Indirect
Sep 28, 2026Common StockCConversionDisposed−769,601$0.00$00Indirect
Sep 28, 2026Common StockCConversionDisposed−564,187$0.00$00Indirect
Sep 28, 2026Common StockCConversionDisposed−7,127,019$0.00$00Indirect
Sep 28, 2026Common StockCConversionDisposed−1,333,975$0.00$00Indirect
Sep 28, 2026Common StockCConversionDisposed−513,067$0.00$00Indirect
Sep 28, 2026Common StockCConversionDisposed−256,448$0.00$00Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.

Referenced by the price of 8 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)